At a glance
ClinicalIndex Comparison RecordN/ACompleted· 9 enrolled
Drug / intervention
sapropterin dihydrochloridedrug
Likely dose
sapropterin dihydrochloride 10mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Kuvan® (Sapropterin Dihydrochloride) for Improving Gastric Accommodation in Women With Diabetic Gastroparesis (KIGA-DG)
In Brief
A clinical study evaluating sapropterin dihydrochloride for Gastroparesis. Completed, enrolled 9 participants across 1 site.
Detailed Summary
Kuvan® (sapropterin dihydrochloride) for Improving Gastric Accommodation in Women with Diabetic Gastroparesis (KIGA-DG)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastroparesis
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2010
First PostedJun 2010
Primary CompletionNov 2012
TodayJul 2026
First PostedJun 2, 2010
Enrollment StartMay 1, 2010
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 16.1 years ago
Interventions
sapropterin dihydrochloridedrug
sapropterin dihydrochloride: 10mg/kg/day